Is a “second look operation” justified in suspected recurrences after abdominal cancer surgery?

Ellis, Harold

doi:10.1002/bjs.1800621020

Cited by 16 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Which approach was to be preferred remained unknown. At the beginning of the 1970s, encouraging results in terms of overall survival were reported and were attributed to the second-look strategy, although controversial results have subsequently been published without any further findings supporting additional surgery without the evidence of recurrent disease [11][12][13].…”

Section: The History Of Metastasectomy In Crcmentioning

confidence: 99%

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Petrella,

Danuzzo,

Sibilia

et al. 2024

Cancers

View full text Add to dashboard Cite

Colorectal cancer is the third-most-diagnosed cancer in males and in females, representing 8% of estimated new cases, and the third cause of cancer-related death in both sexes, accounting for 9% of cancer deaths in men and 8% in women. About 20% of patients diagnosed with CRC present metastatic disease. Although lung metachronous or synchronous metastatic spread without other involved sites has been reported in only a small proportion of patients, considering that this tumor is frequently diagnosed, the clinical approach to CRC pulmonary metastases represents a major issue for thoracic surgeons and CRC oncologists. Among patients diagnosed with pulmonary metastases from CRC, about 9–12% are eligible for local treatments with radical intent, including surgical resection, SBRT (stereotactic body radiation therapy) and ablation therapy. Due to the lack of randomized controlled trials among different local strategies, there is no definitive evidence about the optimal approach, although surgical resection is considered the most effective therapeutic option in this clinical scenario. Oncological achievement of primary radical resection, the biology of primary tumor and metastatic sites, disease free interval and or progression free survival are independent prognostic factors which make it possible to define a cohort of patients which might significantly benefit from pulmonary metastasectomy.

show abstract

Section: The History Of Metastasectomy In Crcmentioning

confidence: 99%

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Petrella,

Danuzzo,

Sibilia

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Resection of recurrent cancer after potentially curative resection of colorectal cancer was believed to sometimes lead to "cure" [23][24][25] 1974-80: CEA was shown to detect asymptomatic recurrence of colorectal cancer 10 Methods of detection, imaging, and surgical resection have changed over the intervening 20 years and those committed to resecting metastases may well regard the results of the restored CEA Second Look trial as irrelevant. We take a different view.…”

Section: -78mentioning

confidence: 99%

Operating to remove recurrent colorectal cancer: have we got it right?

Treasure¹,

Monson²,

Fiorentino³

et al. 2014

BMJ

View full text Add to dashboard Cite

“…In 1975, Ellis et al first reported the second-look operation for RePC, a palliative gastrojejunostomy for gastric outlet obstruction but not a curative ReOP. 8 The first retrospective study of curative ReOP was performed by Nakeeb et al in 1995 and included 27 patients who underwent pancreaticoduodenectomy. 9 Since then, studies of ReOP with various designs have been conducted, 10–12 but no randomised controlled trials (RCTs) had been published at the time of our pilot screening.…”

Section: Introductionmentioning

confidence: 99%

Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis

et al. 2018

View full text Add to dashboard Cite

IntroductionAlthough recurrence rate among cases of resected pancreatic cancer are as high as 85%, an optimal treatment for recurrent pancreatic cancer (RePC) has not been established. Previous evidence regarding RePC is scarce, and randomised controlled trials (RCTs) are particularly lacking. The evidence mapping (EM) method has been introduced as a tool intended to complement the conventional systematic review (SR) and meta-analysis (MA) and is suitable for this issue. This review aims to investigate the optimal treatment options for RePC, using a newly developed automatic EM tool. Method and analysisAll study types, including RCTs, non-randomised studies and other forms of observational studies will be included in the SR-EM. The Medline, Embase, Cochrane library and Scopus databases will be searched for reports of five treatment options for local and metastatic recurrences, including re-resection, chemotherapy, radiotherapy, best supportive care and other novel treatments, published from database inception to 30 April 2017. References from relevant studies will be searched manually. If meta-analysis is feasible, the primary outcome measure will be median overall survival. Two independent authors will select the studies and assess the risk of bias, and a third author will resolve discrepancies in consensus meeting. To visualise EM, we will use a novel web-based and open-access mapping programme, Plotting E-Map (PLOEM) (http://plotting-e-map.com). If eligible combinations of interventions for quantitative comparison are identified, we will conduct subgroup MAs using random-effect models and I2 statistics. Publication bias will be visualised using funnel plots.Ethics and disseminationThis study will not use primary data, and therefore formal ethical approval is not required. The findings will be disseminated through peer-reviewed journals and committee conferences.PROSPEROregistration number CRD42016049178.

show abstract

Is a “second look operation” justified in suspected recurrences after abdominal cancer surgery?

Cited by 16 publications

References 5 publications

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Operating to remove recurrent colorectal cancer: have we got it right?

Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis

Contact Info

Product

Resources

About